
Amidst the rapid acceleration of data generation in today’s digitally enabled healthcare systems, the anticipated benefits of data-driven healthcare are not being realised. This gap reflects the technical challenges of fragmented and poor-quality data, as well as the organisational and cultural shortcomings supporting how data are provisioned, managed and governed. In this article, we expand on the emerging concept of a ‘data supply chain’—a system of systems that provisions and manages the demand for and supply of data that is reliable, timely and fulfils the needs of the data consumer. We examine this concept in the context of cancer control, which has implications for healthcare and the context of broader societal trends, including the emergence of a global ‘data economy’ and the data demands associated with artificial intelligence. The foundations of this paradigm are set upon underlying principles that leverage the maintenance and diligent management of metadata to allow the complex network of data supply chains informing complex health-related decisions, such as achieving cancer control, to be scalable and meaningfully connected and traceable. We conclude by outlining the broader sociotechnological implications of adopting the data supply chain paradigm and identify it as a critical capability in addressing cancer control and strengthening health systems more broadly.
Digital and artificial intelligence (AI) pathology have advanced rapidly and are increasingly embedded in translational research, clinical trials and regulated diagnostic devices. Multiple reviews have addressed the underlying computational methods, oncology applications and clinical translation barriers; however, the operational and regulatory infrastructure required to deploy these technologies across the full drug-development pipeline remains under-reviewed. This structured narrative review synthesises peer-reviewed literature and regulatory documents identified through searches of PubMed, Embase and Web of Science between January 2019 and April 2026 (78 sources retained) on the end-to-end ecosystem connecting AI-ready tissue biobanks, preclinical pathology, AI-assisted patient screening, clinical-trial endpoint adjudication, central pathology review, Contract Research Organization (CRO) workflows and US Food and Drug Administration (FDA) regulatory pathways governing In Vitro Diagnostics (IVD), Software as a Medical Device (SaMD) and Companion Diagnostics (CDx). Unlike prior method-centric or oncology-clinician-centric reviews, we focus on the infrastructure between models and patients, including Laboratory Information Systems (LIS), Image Management Systems (IMS), AI orchestration and structured reporting under Clinical Laboratory Improvement Amendments, College of American Pathologists, Good Laboratory Practice, Good Clinical Laboratory Practice, Health Insurance Portability and Accountability Act and FDA frameworks. We provide a vendor-agnostic comparison of integrated pathology platforms, a mapping of FDA regulatory pathways (510(k), De Novo, premarket approval) to digital-pathology product categories, a stage-by-stage map from each drug-development challenge to its enabling infrastructure and regulatory framework, and a critical appraisal of the unresolved bottlenecks that gate broad adoption: domain shift, interpretability, annotation cost, algorithmic bias, external validation, regulatory uncertainty and reimbursement. A governed, interoperable LIS, IMS and AI ecosystem is a prerequisite for translating digital-pathology research into regulator-grade evidence. Priorities include external validation against reporting standards (Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis - Artificial Intelligence (TRIPOD-AI), Checklist for Artificial Intelligence in Medical Imaging (CLAIM), Development and Early-stage Clinical Identification and Delegation Evaluation of Artificial Intelligence (DECIDE-AI)), harmonisation with the EU AI Act and EU Medical Device Regulation and cost-effectiveness evaluation in real-world deployment.
Global cancer treatment costs are rising unsustainably, mainly due to drug expenses. Immunotherapeutics and molecular targeted drugs use increased dramatically in recent years, despite modest disease-specific survival gains and potential harm. Prescription rates for immune checkpoint inhibitor immunotherapy antibodies (ICIs) have multiplied. The global market for ICIs targeting the anti-programmed cell death-1 (PD1) receptor was US$40.5–48.7 billion in 2024 and continued rise is expected. Pembrolizumab (Keytruda) and Nivolumab (Opdivo) are the most prescribed anti-PD1 therapies, initially for melanoma and now across many tumours. Registration approvals vary from 1 year adjuvantly to open-ended duration for advanced cancer. Demand is high because ICIs can provide durable responses and improve survival, particularly for metastatic disease and in difficult-to-treat cancers. Use is also increasing in adjuvant settings though long-term survival benefits remain unproven. The trade-off for patients is repeated treatment visits, incurring personal costs and impaired activities of daily living in home and/or workplace. Furthermore, while ICIs are generally safe, significant healthcare costs occur in managing complex and life-threatening toxicities on or after treatment. Escalating expenditure is exacerbating inequalities of drug access globally.Evidence suggests current anti-PD1 dosing may be overtreatment. Pharmacokinetic and pharmacodynamic properties of ICIs differ from those of traditional cytotoxic drugs and higher ICI doses may not improve efficacy. Consequently, there is growing interest in de-escalation strategies to optimise care. Researchers design de-escalation trials to lower the amount of drug administered through decreasing dosage, frequency or duration. De-escalation aims to ease the burden on patients and healthcare systems.
Objectives To examine the incidence of and factors associated with new-onset depression following colorectal cancer (CRC) diagnosis and its association with all-cause and CRC-specific mortality.Design Population-based retrospective cohort study using linked administrative health databases.Setting British Columbia, Canada.Participants Individuals diagnosed with CRC from 2010 to 2017 without a history of physician-recorded depression diagnoses in the 5 years preceding the CRC diagnosis.Main outcome measures New-onset depression following CRC diagnosis was identified using International Classification of Diseases (ICD)-9 and ICD-10 diagnostic codes. Cumulative incidence and incidence rates of new-onset depression were estimated, and factors associated with new-onset depression were examined using Cox proportional hazards models. Depression was modelled as a time-varying exposure in mortality analyses, with Cox proportional hazards models used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for all-cause and CRC-specific mortality.Results Among 13 986 patients with CRC (55.2% males, mean age 66.0), the 5-year cumulative incidence of new-onset depression among those without a history of depression was 6.63% following CRC diagnosis. Incidence rates were highest in the first year post-CRC diagnosis (3.54 per 100 person-years), indicating that new-onset depression was most common early after diagnosis. Factors associated with new-onset depression included female sex (HR 1.40 (95% CI 1.22 to 1.61)) and stage 4 disease (HR 1.77 (95% CI 1.34 to 2.33)). New-onset depression after CRC diagnosis was associated with 97% higher all-cause mortality (HR 1.97 (95% CI 1.74 to 2.23)) and 73% higher CRC-specific mortality (HR 1.73 (95% CI 1.48 to 2.03)).Conclusions The cumulative incidence of new-onset depression increased over time, with incidence rates highest in the first year following CRC diagnosis. New-onset depression after CRC diagnosis was associated with higher all-cause and CRC-specific mortality. Findings highlight the importance of early identification of patients at high risk for depression and consideration of longitudinal mental healthcare in CRC care.